Biochemical methods employed for PrPres allotypes profiling are reviewed and compared with the latest mass spectrometric approaches. Emphasis is put on the advantages offered by a recently proposed electrospray strategy.
CollingeJ., “Prion diseases of humans and animals: Their causes and molecular basis”, Annu. Rev. Neurosci.24, 519 (2001).
2.
BrownP. and BradleyR., “1755 and all that: A historical primer of transmissible spongiform encephalopathy”, Brit. Med. J.317, 1688 (1998).
3.
PocchiariM., “Prions and related neurological diseases”, Mol. Aspects Med.15, 195 (1994).
4.
WillR.G.IronsideJ.W.ZeidlerM.CousensS.N.EstibeiroK.AlperovitchA.PoserS.PocchiariM.HofmanA. and SmithP.G., “A new variant of Creutzfeldt-Jakob disease in the UK”, Lancet347, 921 (1996).
5.
BruceM.E.WillR.G.IronsideJ.W.McConnellI.DrummondD.SuttieA.McCardleL.ChreeA.HopeJ.BirkettC.CousensS.FraserH. and BostockC.J., “transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent”, Nature389, 498 (1997).
6.
GoldfarbL.G., “Kuru: The old epidemic in a new mirror”Microbes Infect.4, 875 (2002).
7.
BrownP.PreeceM.BrandelJ.P.SatoT.McShaneL.ZerrI.FletcherA.WillR.G.PocchiariM.CashmanN.R.d'AignauxJ.H.CervenakovaL.FradkinJ.SchonbergerL.B. and CollinsS.J., “Iatrogenic Creutzfeldt-Jakob disease at the millennium”, Neurology55, 1075 (2000).
8.
van DuijnC.M.Delasnerie-LaupretreN.MasulloC.ZerrI.de SilvaR.WientjensD.P.BrandelJ.P.WeberT.BonavitaV.ZeidlerM.AlperovitchA.PoserS.GranieriE.HofmanA. and WillR.G., “Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993–95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD)”, Lancet351, 1081 (1998).
9.
ZerrI.BrandelJ.P.MasulloC.WientjensD.de SilvaR.ZeidlerM.GranieriE.SampaoloS.van DuijnC.Delasnerie-LaupretreN.WillR. and PoserS., “European surveillance on Creutzfeldt-Jakob disease: A case-control study for medical risk factors”, J. Clin. Epidemiol.53, 747 (2000).
10.
WardH.J.EveringtonD.CroesE.A.AlperovitchA.Delasnerie-LaupretreN.ZerrI.PoserS. and van DuijnC.M., “Sporadic Creutzfeldt-Jakob disease and surgery: A case-control study using community controls”, Neurology59, 543 (2002).
11.
PanK.M.BaldwinM.NguyenJ.GassetM.SerbanA.GrothD.MehlhornI.HuangZ.FletterickR.J.CohenF.E. and PrusinerS.B., “Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins”, Proc. Natl. Acad. Sci. USA90, 10962 (1993).
12.
BoltonD.C.McKinleyM.P. and PrusinerS.B., “Identification of a protein that purifies with the scrapie prion”, Science218, 1309 (1982).
13.
PrusinerS.B., “Prions”, Proc. Natl. Acad. Sci. USA95, 13363 (1998).
14.
ChesebroB., “BSE and prions: Uncertainties about the agent”, Science279, 42 (1998).
15.
RachidiW.ViletteD.GuiraudP.ArlottoM.RiondelJ.LaudeH.LehmannS. and FavierA., “Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery”, J. Biol. Chem.278, 9064 (2003).
16.
ChenS.MangeA.DongL.LehmannS. and SchachnerM., “Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival”, Mol. Cell. Neurosci.22, 227 (2003).
17.
MartinsV.R.LindenR.PradoM.A.WalzR.SakamotoA.C.IzquierdoI. and BrentaniR.R., “Cellular prion protein: On the road for functions”, FEBS Lett.512, 25 (2002).
18.
CaugheyB.NearyK.BullerR.ErnstD.PerryL.L.ChesebroB. and RaceR.E., “Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells”, J. Virol.64, 1093 (1990).
19.
BoltonD.C.McKinleyM.P. and PrusinerS.B., “Identification of a protein that purifies with the scrapie prion”, Science218, 1309 (1982).
20.
AlperovitchA.ZerrI.PocchiariM.MitrovaE.de Pedro CuestaJ.HegyiI.CollinsS.KretzschmarH.van DuijnC. and WillR.G., “Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease”, Lancet353, 1673 (1999).
21.
KovacsG.G.TrabattoniG.HainfellnerJ.A.IronsideJ.W.KnightR.S. and BudkaH., “Mutations of the prion protein gene phenotypic spectrum”, J. Neurol.249, 1567 (2002).
22.
PoulterM.BakerH.F.FrithC.D.LeachM.LofthouseR.RidleyR.M.ShahT.OwenF.CollingeJ.BrownJ.HardyJ.MullanM.J.HardingA.E.BennettC.DoshiR. and CrowT.J., “Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies”, Brain115, 675 (1992).
23.
GoldfarbL.G.PetersonR.B.TabatonM.BrownP.LeBlancA.C.MontagnaP.CortelliP.JulienJ.VitalC.PendelburyW.W.HaltiaM.WillsP.R.HauwJ.J.McKeeverP.E.MonariL.SchrankB.SwergoldG.D.Autilio-GambettiL.GajdusekD.C.LugaresiE. and GambettiP., “Fatal familial insomnia and familial Creutzfeld-Jakob disease: Disease phenotype determined by a DNA polymorphism”, Science258, 806 (1992).
24.
DlouhyS.R.HsiaoK.FarlowM.R.ForoudT.ConneallyP.M.JohnsonP.PrusinerS.B.HodesM.E. and GhettiB., “Linkage of the Indiana kindred of Gerstmann–Straussler–Scheinker disease to the prion protein gene”, Nat. Genet.1, 64 (1992).
25.
PocchiariM.SalvatoreM.CutruzzolàF.GenuardiM.AllocatelliC.T.MasulloC.MacchiG.AlemaG.GalganiS.XiY.G.PetraroliR.SilvestriniM.C. and BrunoriM., “A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease”, Ann. Neurol.34, 802 (1993).
26.
BrownP.GibbsC.J.JrRodgers-JohnsonP.AsherD.M.SulimaM.P.BacoteA.GoldfarbL.G. and GajdusekD.C., “Human spongiform encephalopathy: The National Institutes of Health series of 300 cases of experimentally transmitted disease”, Ann. Neurol.35, 513 (1994).
27.
TateishiJ.BrownP.KitamotoT.HoqueZ.M.RoosR.WollmanR.CervenakovaL. and GajdusekD.C., “First experimental transmission of fatal familial insomnia”, Nature376, 434 (1995).
28.
CollingeJ.PalmerM.S.SidleK.C.GowlandI.MedoriR.IronsideJ. and LantosP., “Transmission of fatal familial insomnia to laboratory animals”, Lancet346, 569 (1995).
29.
BrunoriM. and TalbotB., “A mechanism for prion replication”, Nature314, 676 (1985).
30.
SwietnickiW.MorillasM.ChenS.G.GambettiP. and SurewiczW.K., “Aggregation and fibrillization of the recombinant human prion protein huPrP90–231”, Biochemistry39, 424 (2000).
31.
KuwataK.LiH.YamadaH.LegnameG.PrusinerS.B.AkasakaK. and JamesT.L., “Locally disordered conformer of the hamster prion protein: A crucial intermediate to PrPSc”, Biochemistry41, 12277 (2002).
32.
ComeJ.H.FraserP.E. and LansburyP.T.Jr, “A kinetic model for amyloid formation in the prion diseases: Importance of seeding”, Proc. Natl. Acad. Sci. USA90, 5959 (1993).
33.
StahlN. and PrusinerS.B., “Prions and prion proteins”, FASEB J.5, 2799 (1991).
34.
ZanussoG.RighettiP.G.FerrariS.TerrinL.FarinazzoA.CardoneF.PocchiariM.RizzutoN. and MonacoS., “Two-dimensional mapping of three phenotype-associated isoforms of the prion protein in sporadic Creutzfeldt-Jakob disease”, Electrophoresis23, 347 (2002).
35.
DiringerH.BeekesM.ÖzelM.SimonD.QueckI.CardoneF.PocchiariM. and IronsideJ.W., “Highly infectious purified preparations of disease-specific amyloid of transmissible spongiform encephalopathies are not devoid of nucleic acids of viral size”, Intervirology40, 238 (1997).
36.
StahlN.BaldwinM.A.TeplowD.B.HoodL.GibsonB.W.BurlingameA.L. and PrusinerS.B., “Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing”, Biochemistry32, 1991 (1993).
37.
GhettiB.PiccardoP.SpillantiniM.G.IchimiyaY.PorroM.PeriniF.KitamotoT.TateishiJ.SeilerC.FrangioneB.BugianiO.GiacconeG.PrelliF.GoedertM.DlouhyS.R. and TagliaviniF., “Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: The phenotype of the stop codon 145 mutation in PRNP”, Proc. Natl. Acad. Sci. USA93, 744 (1996).
38.
ChenS.G.ParchiP.BrownP.CapellariS.ZouW.CochranE.J.Vnencak-JonesC.L.JulienJ.VitalC.MikolJ.LugaresiE.Autilio-GambettiL. and GambettiP., “Allelic origin of the abnormal prion protein isoform in familial prion diseases”, Nat. Med.3, 1009 (1997).
39.
GabizonR.TellingG.MeinerZ.HalimiM.KahanaI. and PrusinerS.B., “Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease”, Nat. Med.2, 59 (1996).
40.
KitamotoT.YamaguchiK.Doh-UraK. and TateishiJ., “A prion protein missense variant is integrated in kuru plaque cores in patients with Gerstmann-Straussler syndrome”, Neurology41, 306 (1991).
41.
BarbantiP.FabbriniG.SalvatoreM.PetraroliR.CardoneF.MarasB.EquestreM.MacchiG.LenziG.L. and PocchiariM., “Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann–Straussler–Sheinker disease (PrP-P102L mutation)”, Neurology47, 734 (1996).
42.
ParchiP.ZouW.WangW.BrownP.CapellariS.GhettiB.KoppN.Schulz-SchaefferW.J.KretzschmarH.A.HeadM.W.IronsideJ.W.GambettiP. and ChenS.G., “Genetic influence on the structural variations of the abnormal prion protein”, Proc. Natl. Acad. Sci. USA97, 10168 (2000).
43.
TagliaviniF.PrelliF.PorroM.RossiG.GiacconeG.FarlowM.R.DlouhyS.R.GhettiB.BugianiO. and FrangioneB., “Amyloid fibrils in Gerstmann-Straussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele”, Cell79, 695 (1994).
44.
SilvestriniM.C.CardoneF.MarasB.PucciP.BarraD.BrunoriM. and PocchiariM., “Identification of the prion protein allotypes which accumulate in the brain of sporadic and familial Creutzfeldt-Jakob disease patients”, Nat. Med.3, 521 (1997).
45.
BarberM.BordoliR.S.GarnerG.V.GordonD.B.SedgwickR.D.TetlerL.W. and TylerA.N., “Fast-atom-bombardment mass spectra of enkephalins”, Biochem. J.197, 401 (1981).
46.
BenninghovenA.RudenauerF.G. and WernerH.W., in Secondary Ion Mass Spectrometry: Basic Concepts, Instrumental Aspects, Applications, and Trends, Vol. 86, Chemical Analysis Series. John Wiley & Sons, New York, USA (1987).
47.
KarasM. and HillenkampF., “Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons”, Anal. Chem.60, 2299 (1988).
48.
FennJ.B.MannM.MengC.K.WongandS.F. and WhitehouseC.M., “Electrospray ionization for mass spectrometry of large biomolecules”, Science246, 64 (1989).
49.
BaldwinM.A., “Mass spectrometric analysis of prion proteins”, Adv. Protein Chem.57, 29 (2001).
50.
ChenS.G.ZouW.ParchiP. and GambettiP., “PrP(Sc) typing by N-terminal sequencing and mass spectrometry”, Arch. Virol. Suppl.16, 209 (2000).
51.
QinK.YangY.MastrangeloP. and WestawayD., “Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting”, J. Biol. Chem.277, 1981 (2002).
52.
WhittalR.M.BallH.L.CohenF.E.BurlingameA.L.PrusinerS.B. and BaldwinM.A., “Copper binding to octarepeat peptides of the prion protein monitored by mass spectrometry”, Protein Sci.9, 332 (2000).
53.
SauerS.LechnerD.BerlinK.PlanconC.HeuermannA.LehrachH. and GutI.G., “Full flexibility genotyping of single nucleotide polymorphisms by the GOOD assay”, Nucleic Acid Res.28, E100 (2000).
54.
HumenyA.SchiebelK.SeeberS. and BeckerC.M., “Identification of polymorphisms within the bovine prion protein gene (Prnp) by DNA sequencing and genotyping by MALDI-TOF-MS”, Neurogenetics4, 59 (2002).
55.
KrebsS.MedugoracI.SeichterD. and ForsterM., “RNaseCut: A MALDI mass spectrometry-based method for SNP discovery”, Nucleic Acid Res.31, E37 (2003).
56.
TagliaviniF.LievensP.M.TranchantC.WarterJ.M.MohrM.GiacconeG.PeriniF.RossiG.SalmonaM.PiccardoP.GhettiB.BeavisR.C.BugianiO.FrangioneB. and PrelliF., “A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann–Straussler–Scheinker disease A117V”, J. Biol. Chem.276, 6009 (2001).
57.
MedzihradszkyK.F.CampbellJ.M.BaldwinM.A.FalikA.M.JuhaszP.VestalM.L. and BurlingameA.L., “The characteristics of peptide collision-induced dissociation using a high-performance MALDI-TOF/TOF tandem mass spectrometer”, Anal. Chem.72, 552 (2000).
58.
GriffinT.J.GygiS.P.RistB.AebersoldR.LobodaA.JilkineA.EnsW. and StandingK.G., “Quantitative proteomic analysis using a MALDI quadrupole time-of-flight mass spectrometer”, Anal. Chem.73, 978 (2001).
59.
ShevchenkoA.SunyaevS.LobodaA.ShevchenkoA.BorkP.EnsW. and StandingK.G., “Charting the proteomes of organisms with unsequenced genomes by MALDI-quadrupole time-of-flight mass spectrometry and BLAST homology searching”, Anal. Chem.73, 5066 (2001).
60.
KrutchinskyA.N.KalkumM. and ChaitB.T., “Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer”, Anal. Chem.73, 5066 (2001).
61.
ShevchenkoA.JensenO.N.PodtelejnikovA.V.SaglioccoF.WilmM.VormO.MortensenP.ShevchenkoA.BoucherieI.I. and MannM., “Linking genome and proteome by mass spectrometry: Large-scale identification of yeast proteins from two dimensional gels”, Proc. Natl. Acad. Sci. USA93, 14440 (1996).
62.
PattersonS.D. and AebersoldR.H., “Proteomics: The first decade and beyond”, Nat. Genet.33, 311 (2003).
63.
SchininàM.E.MarasB.CardoneF.ManconeC.PrincipeS.Di BariM.A.ParchiP. and PocchiariM., “Prion protein allotype profiling by mass spectrometry”, Pure Appl. Chem.75, 311 (2003).
64.
KusterB. and MannM., “Identifying proteins and post-translational modifications by mass spectrometry”, Curr. Opin. Struct. Biol.8, 393 (1998).
65.
PattersonS.D. and AebersoldR., “Mass spectrometric approaches for the identification of gel-separated proteins”, Electrophoresis16, 1791 (1995).
66.
YatesJ.R.III, “Mass spectrometry and the age of the proteome”, J. Mass Spectrom.33, 1 (1998).
67.
WilkinsM.R.HochstrasserD.F.SanchezJ.C.BairochA. and AppelR.D., “Integrating two-dimensional gel databases using the Melanie II software”, Trends Biochem. Sci.21, 496 (1996).
